Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Royalty Pharma plc (RPRX)

36.03   -0.27 (-0.74%) 03-31 16:00
Open: 36.28 Pre. Close: 36.3
High: 36.32 Low: 35.955
Volume: 1,760,291 Market Cap: 15,967(M)

Technical analysis

as of: 2023-03-31 4:21:48 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 44.6     One year: 52.09
Support: Support1: 34.78    Support2: 32.68
Resistance: Resistance1: 38.18    Resistance2: 44.6
Pivot: 35.26
Moving Average: MA(5): 36.66     MA(20): 34.97
MA(100): 38.89     MA(250): 40.67
MACD: MACD(12,26): 0     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 65.5     %D(3): 71.9
RSI: RSI(14): 51.6
52-week: High: 44.75  Low: 32.68
Average Vol(K): 3-Month: 1,928 (K)  10-Days: 2,078 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RPRX ] has closed below upper band by 34.5%. Bollinger Bands are 67.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 36.37 - 36.63 36.63 - 36.82
Low: 35.28 - 35.63 35.63 - 35.9
Close: 35.55 - 36.02 36.02 - 36.38

Company Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Headline News

Wed, 29 Mar 2023
Royalty Pharma plc (NASDAQ:RPRX) Given Average Rating of "Buy ... - MarketBeat

Mon, 27 Mar 2023
Royalty Pharma Announces 1 Billion Share Repurchase Program - Best Stocks

Mon, 27 Mar 2023
Royalty Pharma plc (RPRX) Stock: How Does it Score on Valuation Metrics? - InvestorsObserver

Thu, 23 Mar 2023
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million - Yahoo Finance

Thu, 23 Mar 2023
PureTech Health and Royalty Pharma Enter into KarXT Royalty ... - BioSpace

Tue, 21 Mar 2023
Robeco Institutional Asset Management B.V. Buys 30450 Shares of ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 441 (M)
Shares Float 377 (M)
% Held by Insiders 24.9 (%)
% Held by Institutions 67.9 (%)
Shares Short 7,100 (K)
Shares Short P.Month 7,470 (K)

Stock Financials

EPS 1.92
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 13.48
Profit Margin (%) 22.5
Operating Margin (%) 41.9
Return on Assets (ttm) 3.3
Return on Equity (ttm) 8.5
Qtrly Rev. Growth -2.1
Gross Profit (p.s.) 4.17
Sales Per Share 5.1
EBITDA (p.s.) 2.16
Qtrly Earnings Growth 36.2
Operating Cash Flow 2,060 (M)
Levered Free Cash Flow -1,480 (M)

Stock Valuations

PE Ratio 18.66
PEG Ratio 0.9
Price to Book value 2.67
Price to Sales 7.06
Price to Cash Flow 7.71

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2022-03-14
Ex-Dividend Date 2022-02-16
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.